MICHAEL S WEISS
CIK 1038977 · Executive Vice Chairman · last filed 2026-03-20
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$1.27B
Companies
9
Total Filings
65
Lifetime Open-Market Net
-$5.57M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| FBIOP | Executive Vice Chairman | 2,276,562 | $20.71 | $47.15M | $1.25M | 10 | 2026-03-20 |
| TGTX | CEO | 24,212,300 | $49.52 | $1.20B | -$3.35M | 23 | 2026-01-09 |
| Checkpoint Therapeutics, Inc. (CKPT) Delisted | Director | 187,007 | $4.26 | $796.6K | $0 | 9 | 2025-05-30 |
| MBIO | Director | 100,060 | $0.74 | $74.0K | $0 | 5 | 2023-07-07 |
| ATXI | Director | 24,663 | $0.35 | $8.7K | $0 | 1 | 2018-08-08 |
| FBIO | Exec. VC - Strategic Dev. | 8,001,170 | $2.77 | $22.16M | $0 | 2 | 2017-01-27 |
| Fortress Biotech, Inc. (CNDO) Delisted | Exec. VC - Strategic Dev. | 6,938,038 | — | — | $1.61M | 3 | 2014-11-10 |
| KERYX BIOPHARMACEUTICALS INC (KERX) Delisted | Chief Executive Officer | 1,465,137 | — | — | -$5.08M | 6 | 2010-05-12 |
| XTLB | Director | — | $2.13 | — | $0 | 1 | 2008-11-04 |
Recent Filings · Page 6 of 7
65 filingsForm 4 transactions across all companies, newest first.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2014-02-24 | Fortress Biotech, Inc. (CNDO) Delisted | Grant (A) | +3,958,692 | $0 | EDGAR |
| 2014-01-02 | TGTX | Grant (A) | +491,920 | $0 | EDGAR |
| 2013-12-23 | Fortress Biotech, Inc. (CNDO) Delisted | Grant (A) | +1,979,346 | $0 | EDGAR |
| 2013-12-12 | TGTX | Buy (P) | +10,000 | $34.3K | EDGAR |
| 2013-01-02 | — | Grant (A) | +486,743 | $0 | |
| 2012-09-11 | — | Buy (P) | +150,000 | $337.5K | |
| 2012-05-17 | — | Mixed | +5,026,060 | $9.4K | |
| 2010-05-12 | KERYX BIOPHARMACEUTICALS INC (KERX) Delisted | Sell (S) | −627,649 | -$3.39M | EDGAR |
| 2010-04-13 | KERYX BIOPHARMACEUTICALS INC (KERX) Delisted | Mixed | −110,200 | -$1.30M | EDGAR |
| 2009-06-12 | — | — | — | $0 |
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.